Hemogenyx Pharmaceuticals (LON:HEMO) Trading 17.6% Higher - Here's Why

Key Points

• Hemogenyx Pharmaceuticals' stock price rose 17.6% during Monday's trading, reaching GBX 1,230 ($16.68) at its peak, significantly higher than its previous close of GBX 1,010 ($13.69).
• The trading volume surged by 144%, with 143,993 shares changing hands compared to the average of 59,083 shares.
• Hemogenyx is a preclinical-stage biotechnology company focusing on treatments for blood diseases, including therapies for acute myeloid leukaemia and bone marrow transplants.

Hemogenyx Pharmaceuticals Plc (LON:HEMO - )'s stock price traded up 17.6% during mid-day trading on Monday . The stock traded as high as GBX 1,230 ($16.68) and last traded at GBX 1,188 ($16.11). 143,993 shares changed hands during trading, an increase of 144% from the average session volume of 59,083 shares. The stock had previously closed at GBX 1,010 ($13.69).

Hemogenyx Pharmaceuticals Trading Up 19.3%

The company has a debt-to-equity ratio of 90.87, a current ratio of 4.38 and a quick ratio of 6.72. The company has a fifty day moving average of GBX 295.78 and a 200-day moving average of GBX 225.11. The firm has a market capitalization of £56.96 million, a PE ratio of -665.38 and a beta of 3.14.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.